A detailed history of Everett Harris & CO transactions in Organon & Co. stock. As of the latest transaction made, Everett Harris & CO holds 48,532 shares of OGN stock, worth $887,650. This represents 0.01% of its overall portfolio holdings.

Number of Shares
48,532
Previous 49,932 2.8%
Holding current value
$887,650
Previous $938,000 7.04%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$17.45 - $21.96 $24,430 - $30,744
-1,400 Reduced 2.8%
48,532 $1 Million
Q1 2024

Apr 19, 2024

SELL
$13.78 - $18.8 $24,404 - $33,294
-1,771 Reduced 3.43%
49,932 $938,000
Q4 2023

Jan 18, 2024

SELL
$10.95 - $17.32 $327,240 - $517,608
-29,885 Reduced 36.63%
51,703 $745,000
Q3 2023

Oct 23, 2023

SELL
$16.59 - $23.77 $54,680 - $78,345
-3,296 Reduced 3.88%
81,588 $1.42 Million
Q2 2023

Jul 26, 2023

BUY
$19.27 - $24.63 $77,600 - $99,185
4,027 Added 4.98%
84,884 $1.77 Million
Q1 2023

Apr 24, 2023

BUY
$21.42 - $32.08 $49,630 - $74,329
2,317 Added 2.95%
80,857 $1.9 Million
Q4 2022

Jan 20, 2023

BUY
$23.31 - $28.61 $1.04 Million - $1.27 Million
44,414 Added 130.15%
78,540 $0
Q3 2022

Oct 21, 2022

BUY
$23.4 - $34.25 $23,470 - $34,352
1,003 Added 3.03%
34,126 $799,000
Q2 2022

Jul 22, 2022

SELL
$31.66 - $38.9 $29,000 - $35,632
-916 Reduced 2.69%
33,123 $1.12 Million
Q1 2022

Apr 22, 2022

SELL
$30.45 - $39.36 $1,705 - $2,204
-56 Reduced 0.16%
34,039 $1.19 Million
Q4 2021

Feb 02, 2022

BUY
$28.67 - $37.13 $145,385 - $188,286
5,071 Added 17.47%
34,095 $1.04 Million
Q3 2021

Nov 03, 2021

BUY
$28.63 - $35.64 $243,841 - $303,545
8,517 Added 41.53%
29,024 $952,000
Q2 2021

Jul 29, 2021

BUY
$28.45 - $38.0 $583,424 - $779,266
20,507 New
20,507 $621,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.65B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Everett Harris & CO Portfolio

Follow Everett Harris & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everett Harris & CO , based on Form 13F filings with the SEC.

News

Stay updated on Everett Harris & CO with notifications on news.